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METHODS: Subjects were randomized in a double-blind
manner to 200mg Panax ginseng (n = 15) or placebo (n
= 15) daily for 8 weeks. The Short Form-36 version 2 
(SF-36v2), a validated general health status questionnaire,
was used to assess HRQOL at baseline, 4 and 8 weeks.
HRQOL between the groups was compared using
repeated measures analysis of covariance. A p-value of
<0.05 was considered statistically signiﬁcant.
RESULTS: There were no signiﬁcant differences in 
baseline demographics and SF-36v2 scores between the
groups. After 4 weeks of therapy, higher scores in social
functioning (Panax ginseng: 54.9 ± 4.6 vs. placebo: 49.2
± 6.5; p = 0.014), mental health (Panax ginseng: 52.2 ±
7.7 vs. placebo: 47.2 ± 7.3; p = 0.075) and the mental
component summary (Panax ginseng: 51.3 ± 7.4 vs.
placebo: 44.3 ± 8.3; p = 0.019) scales were observed in
patients randomized to Panax ginseng; these differences
did not persist to the 8-week timepoint. No other signif-
icant differences in HRQOL between the groups were
found at the 4- and 8-week timepoints. The incidence of
adverse effects was 33% in the Panax ginseng group 
compared to 17% in the placebo group (p = 0.40). 
Subjects given Panax ginseng (58%) were more likely to
state that they received active therapy than subjects given
placebo (17%; p < 0.05).
CONCLUSIONS: Panax ginseng improves aspects of
mental health and social functioning after a 4 weeks of
therapy although these differences attenuate with 
continued use.
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OBJECTIVES: To measure health related quality of life
(HRQOL) of dementia caregivers and to examine 
relationship of caregiving characteristics with caregiver
health status.
METHODS: A convenience sample of 71 caregivers was
selected from local chapters of Alzheimer’s Association in
New York metropolitan area. The caregiver health status
was measured using Short Form 12, Version 2 (SF-12),
general health survey. Hypotheses were formulated and
tested to examine the inﬂuence of caregiving activities on
the self-reported health status of caregivers. Norm-based
physical and mental component summary scores (PCS
and MCS) were computed to investigate associations
between caregiving characteristics and caregiver health
status.
RESULTS: Eighty two percent of the sample were
women. Relatives of the care recipients provided bulk of
caregiving (51%). Professional caregivers who received
ﬁnancial compensation reported higher, statistically sig-
niﬁcant health status scores (PCS = 51.3, p = 0.025; MCS
= 51.2, p = 0.0025) compared to those who did not
receive ﬁnancial compensation (PCS 47.3, p = 0.0165;
MCS = 42.4, p = 0.0005). Higher and signiﬁcant scores
were also reported by caregivers with formal training in
caregiving than those who received no such training (p =
0.009). No signiﬁcant differences were found on HRQOL
scores for caregiving spouses and caregiving children.
There was no association between the health status of
caregivers and the length of time spent in caregiving.
CONCLUSIONS: The type of caregiver relationship to
the care recipient appears to have no bearing on the
HRQOL of caregivers. Financial compensation for care-
giving is associated positively with better health outcomes
for the caregivers. Caregiver health status is not inﬂu-
enced by the length of time spent in providing caregiving
activities.
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OBJECTIVES: To utilize responder rate to demonstrate
the improvement of negative symptoms and quality of 
life (QoL) associated with olanzapine (OLZ) versus
risperidone (RIS).
METHODS: Data were analyzed post-hoc from a 
large, prospective, randomized, 28-week, double-blind
trial, conducted with 339 patients who met the DSM-IV
criteria for schizophrenia, schizophreniform disorder, or
schizoaffective disorder. Three methods of outcome 
measurement (mean score change, proportion of 
responders and time to response) were used to compare
improvement in the Scale for Assessment of Negative
Symptoms (SANS) and the Quality of Life Scale (QLS)
scores across groups.
RESULTS: At the end of the 28-week treatment, signiﬁ-
cantly more OLZ- than RIS-treated patients reached the
thresholds of 30%, 40% and 50% improvement in SANS
and of 20%, 30% and 40% improvement in QLS. OLZ-
patients also demonstrated a more rapid improvement in
SANS and QLS than RIS-patients.
CONCLUSIONS: The greater effectiveness of OLZ
versus RIS was demonstrated by the greater proportion
of patients who had access to a higher level of clinically
relevant response of negative symptoms and improvement
of QoL. Treatment effectiveness may be a better indica-
tor of the chance of achieving superior functional goals.
